N6-Methyladenosine (m6A) is the most widely distributed RNA modification in eukaryotes and its dysregulation has been tied in gastric cancer protumorigenic processes, as well as drug resistance and metastasis. Vir-like m6A methyltransferase associated, also known as KIAA1429, is a crucial regulator of the m6A complex, and thus hypothesized to be involved in the progression of gastric cancer.
Researchers from the Center for Applied Medical Research (CIMA) in Spain have published preclinical data for two new histone deacetylase (HDAC) inhibitors – CM-444 and CM-1758 – being developed for the treatment of acute myeloid leukemia (AML).
Patients with congenital hearing loss could benefit from a gene therapy currently in development. Although there are approaches that could reverse the process in children and young people before it becomes severe, so far, adults do not have any treatment that prevents the progressive deterioration of auditory sensory cells caused by this disease.
Myricx Bio Ltd. has closed the largest series A for a European biotech this year, raising £90 million (US$115.4 million), to take forward antibody-drug conjugates based on novel payload chemistry.
Daiichi Sankyo Co. Ltd. has prepared and tested new 2-azabicyclo[3.1.1]heptane compounds acting as orexin OX2 receptor agonists with potential for the treatment of narcolepsy.
Drug conjugates acting as gonadotropin-releasing hormone (GnRH) receptor ligands have been described in a recent Radionetics Oncology Inc. patent. They are reported to be useful for the diagnosis and treatment of cancer.
Work at Karuna Therapeutics Inc. has led to the identification of substituted tetrahydropyrrolo-pyridinone compounds acting as muscarinic M4 receptor agonists and/or positive allosteric modulators.
RSS
